Search Results - "Galanopoulos, Athanasios"

Νοvel Therapies in High‐Risk Myelodysplastic Syndromes.

Authors: Galanopoulos, Athanasios G. Papi, Christina

Source: European Journal of Haematology. Jun2026, Vol. 116 Issue 6, p744-758. 15p.

Compound Heterozygosity for the C6777T Mutation of the MTHFR Gene and the FII G20210A Mutation of the Prothrombin Gene in Sequential Bilateral Anterior Ischemic Optic Neuropathy.

Authors: Tsiogka, Anastasia Vlachos, Georgios Galanopoulos, Athanasios et al.

Source: Neuro-Ophthalmology. Jun2025, Vol. 49 Issue 3, p193-199. 7p.

Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS).

Authors: Symeonidis, Argiris Diamantopoulos, Panagiotis Galanopoulos, Athanasios et al.

Source: Cancers. May2025, Vol. 17 Issue 9, p1388. 23p.

Intravascular B-cell lymphoma with leukemic presentation: case report and literature review.

Authors: Xanthopoulos, Vasilios Galanopoulos, Athanasios G. Paterakis, Georgios et al.

Source: European Journal of Haematology. Feb2008, Vol. 80 Issue 2, p177-181. 5p. 4 Color Photographs.

Deciphering the role of HMGA2 and let-7 microRNAs in myelodysplastic neoplasms with bone marrow fibrosis.

Authors: Vlachopoulou, Dimitra Kontandreopoulou, Christina-Nefeli Diamantopoulos, Panagiotis T. et al.

Source: Leukemia & Lymphoma. Apr2026, Vol. 67 Issue 5, p1109-1115. 7p.

Reply to Dr Kemal Örnek Regarding Comments on: "Compound Heterozygosity for the C6777T Mutation of the MTHFR Gene and the FII G20210A Mutation of the Prothrombin Gene in Sequential Bilateral Anterior Ischemic Optic Neuropathy".

Authors: Tsiogka, Anastasia Vlachos, Georgios Galanopoulos, Athanasios et al.

Source: Neuro-Ophthalmology. Apr2026, Vol. 50 Issue 2, p206-207. 2p.

Prognostic significance of deletion of the long arm of chromosome 20 in patients with myelodysplastic syndrome (MDS): a study of the Greek MDS Study Group.

Authors: Galanopoulos, Athanasios G. Symeonidis, Argyris Kourakli, Aleka et al.

Source: European Journal of Haematology. Jan2007, Vol. 78 Issue 1, p89-90. 2p.

Leukemic transformation in patients with myelodysplastic syndromes after treatment with granulocyte colony-stimulating factor.

Authors: Diamantopoulos, Panagiotis T. Chatzileonida, Titika Galanopoulos, Athanasios et al.

Source: Leukemia & Lymphoma. Oct2012, Vol. 53 Issue 10, p2069-2072. 4p.

Real‐life experience of luspatercept in transfusion‐dependent lower risk myelodysplastic syndrome patients.

Authors: Bouchla, Anthi Papageorgiou, Sotirios G. Kotsianidis, Ioannis et al.

Source: British Journal of Haematology. Jul2025, Vol. 207 Issue 1, p101-109. 9p.

Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.

Authors: Kontandreopoulou, Christina-Nefeli Diamantopoulos, Panagiotis T. Giannopoulos, Andreas et al.

Source: Leukemia & Lymphoma. Mar2022, Vol. 63 Issue 3, p729-737. 9p.

Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.

Authors: Diamantopoulos, Panagiotis T. Kotsianidis, Ioannis Symeonidis, Argiris et al.

Source: Leukemia & Lymphoma. Jul2019, Vol. 60 Issue 7, p1721-1730. 10p.

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry.

Authors: Diamantopoulos, Panagiotis Koumbi, Dafni Kotsianidis, Ioannis et al.

Source: Cancer Medicine. May2019, Vol. 8 Issue 5, p2056-2063. 8p.

Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia.

Authors: Diamantopoulos, Panagiotis T. Sofotasiou, Maria Georgoussi, Zafiroula et al.

Source: Cancer Medicine. Sep2016, Vol. 5 Issue 9, p2240-2248. 9p.

Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.

Authors: Diamantopoulos, Panagiotis T. Kontandreopoulou, Christina-Nefeli Stafylidis, Christos et al.

Source: Annals of Hematology. Dec2022, Vol. 101 Issue 12, p2711-2717. 7p.

Evidence for regulation of oxidative stress by latent membrane protein 1 oncoprotein in patients with low-grade leukemic B cell lymphoma with latent Epstein-Barr virus infection.

Authors: Papadopoulou, Vasiliki Diamantopoulos, Panagiotis T. Kontandreopoulou, Elina et al.

Source: Leukemia & Lymphoma. Aug2014, Vol. 55 Issue 8, p1904-1909. 6p.

Flow Cytometry as a Diagnostic Tool in the Early Diagnosis of Aggressive Lymphomas Mimicking Life-Threatening Infection.

Authors: Tsagarakis, Nikolaos J. Kentrou, Nektaria A. Kakiopoulos, Georgios et al.

Source: Case Reports in Medicine. 2011, p1-8. 8p. 1 Color Photograph, 2 Charts, 2 Graphs.

The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.

Authors: Diamantopoulos, Panagiotis T. Symeonidis, Argiris Pappa, Vasiliki et al.

Source: British Journal of Haematology. Mar2021, Vol. 192 Issue 6, p978-987. 10p.

Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.

Authors: Diamantopoulos, Panagiotis T. Kontandreopoulou, Christina-Nefeli Vassilakopoulos, Theodoros et al.

Source: Annals of Hematology. Jun2019, Vol. 98 Issue 6, p1383-1392. 10p.

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.

Authors: Papageorgiou, Sotirios G. Kotsianidis, Ioannis Kontos, Christos K. et al.

Source: Leukemia Research. Aug2018, Vol. 71, p55-59. 5p.

Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway.

Authors: Pavlaki, Konstantia Pontikoglou, Charalampos G. Demetriadou, Anthi et al.

Source: Stem Cells & Development. Jul2014, Vol. 23 Issue 14, p1568-1581. 14p.